Published in J Am Acad Dermatol on July 03, 2009
Bitemporal scalp, lip and tongue necrosis in giant cell arteritis: a rare presentation. Indian J Dermatol (2013) 0.96
[Bitemporal scalp necrosis : a very rare manifestation of giant cell arteritis]. Z Rheumatol (2012) 0.78
Bilateral scalp necrosis as a rare but devastating complication of giant cell arteritis. Clin Rheumatol (2014) 0.76
Scalp necrosis in giant cell arteritis after initiation of therapeutic corticosteroids. J Am Acad Dermatol (2010) 0.75
Forehead necrosis, one of the many facades of giant cell arteritis. BMJ Case Rep (2015) 0.75
Cutaneous Manifestations of Medium- and Large-Vessel Vasculitis. Clin Rev Allergy Immunol (2017) 0.75
[Skin manifestations of different forms of vasculitis]. Z Rheumatol (2013) 0.75
Spinal cord infarction in giant cell arteritis associated with scalp necrosis. Rheumatol Int (2014) 0.75
Cutaneous nocardiosis manifesting as a frontal mass in a patient with giant cell arteritis. Clujul Med (2017) 0.75
Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci (2003) 2.94
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev (2005) 2.42
Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol (2006) 2.00
The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med (2010) 1.70
Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol (2003) 1.68
RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol (2011) 1.60
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol (2007) 1.59
Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med (2006) 1.59
Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts. J Invest Dermatol (2009) 1.55
Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol (2004) 1.52
Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol (2007) 1.46
Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res (2006) 1.42
FK506 controls CD40L-induced systemic autoimmunity in mice. J Invest Dermatol (2006) 1.42
Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol (2006) 1.41
IκBζ is a transcriptional key regulator of CCL2/MCP-1. J Immunol (2013) 1.41
Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol (2003) 1.33
Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol (2008) 1.28
Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc (2011) 1.27
alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem (2004) 1.26
Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med (2003) 1.26
Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One (2010) 1.24
Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J (2003) 1.22
Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B. J Invest Dermatol (2005) 1.16
Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol (2002) 1.12
Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol (2004) 1.11
Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology (2009) 1.10
Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol (2007) 1.07
alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum (2009) 1.06
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol (2006) 1.06
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther (2009) 1.05
Successful treatment of generalized eruptive histiocytoma with PUVA. J Dtsch Dermatol Ges (2007) 1.05
Increased cAMP levels modulate transforming growth factor-beta/Smad-induced expression of extracellular matrix components and other key fibroblast effector functions. J Biol Chem (2009) 1.04
Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab (2008) 1.02
Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. J Biol Chem (2003) 1.02
Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol (2009) 1.00
Dendritic cell-derived IL-12p40 homodimer contributes to susceptibility in cutaneous leishmaniasis in BALB/c mice. J Immunol (2007) 0.98
Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Ann Neurol (2014) 0.97
Cohort profile: Greifswald approach to individualized medicine (GANI_MED). J Transl Med (2014) 0.97
Immune response modifiers--mode of action. Exp Dermatol (2006) 0.97
Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol (2002) 0.97
Altered heparan sulfate structure in mice with deleted NDST3 gene function. J Biol Chem (2008) 0.97
Surgical treatment of persistent macrocheilia in patients with Melkersson-Rosenthal syndrome and cheilitis granulomatosa. Arch Dermatol (2005) 0.97
Role of vasculature in atopic dermatitis. J Allergy Clin Immunol (2006) 0.96
Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol (2006) 0.94
[Current situation of dermatologic surgery in Germany]. J Dtsch Dermatol Ges (2006) 0.94
Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol (2007) 0.94
Subcutaneous infection with S. aureus in mice reveals association of resistance with influx of neutrophils and Th2 response. J Invest Dermatol (2010) 0.93
α-MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation. J Invest Dermatol (2012) 0.93
Neutral endopeptidase and angiotensin-converting enzyme -- key enzymes terminating the action of neuroendocrine mediators. Exp Dermatol (2004) 0.93
The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. PLoS One (2010) 0.92
Increasing sampling interval in cerebral perfusion CT: limitation for the maximum slope model. Acad Radiol (2009) 0.92
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis (2008) 0.91
Solar-simulated ultraviolet radiation-induced upregulation of the melanocortin-1 receptor, proopiomelanocortin, and alpha-melanocyte-stimulating hormone in human epidermis in vivo. J Invest Dermatol (2004) 0.91
Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of alpha-melanocyte-stimulating hormone in human dermal papilla cells. Endocrinology (2005) 0.91
Chronic pruritus: targets, mechanisms and future therapies. Drug News Perspect (2008) 0.90
Malignant fibrous histiocytoma of the face: report of a case. Head Face Med (2007) 0.90
Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol (2009) 0.90
Successful treatment of palmoplantar hyperkeratotic psoriasis with a combination of etanercept and alitretinoin. J Clin Aesthet Dermatol (2011) 0.90
The melanocortin system in articular chondrocytes: melanocortin receptors, pro-opiomelanocortin, precursor proteases, and a regulatory effect of alpha-melanocyte-stimulating hormone on proinflammatory cytokines and extracellular matrix components. Arthritis Rheum (2009) 0.89
Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol (2010) 0.89
Pathogenesis of pruritus. J Dtsch Dermatol Ges (2011) 0.89
MRSA eradication in dermatologic outpatients - theory and practice. J Dtsch Dermatol Ges (2011) 0.88
Perfusion CT in acute stroke: prediction of vessel recanalization and clinical outcome in intravenous thrombolytic therapy. Eur Radiol (2007) 0.87
Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol (2010) 0.86
Melanocortins in fibroblast biology--current update and future perspective for dermatology. Exp Dermatol (2004) 0.86
Tissue microarray analysis of RANKL in cutaneous lupus erythematosus and psoriasis. Exp Dermatol (2011) 0.85
Site of blood vessel damage and relevance of CD18 in a murine model of immune complex-mediated vasculitis. J Invest Dermatol (2006) 0.85
The treatment of atopic dermatitis with topical immunomodulators. Clin Dermatol (2003) 0.84
Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm Venereol (2007) 0.83
An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology (2007) 0.83
KdPT, a tripeptide derivative of alpha-melanocyte-stimulating hormone, suppresses IL-1 beta-mediated cytokine expression and signaling in human sebocytes. J Immunol (2010) 0.83
Fatty acids differentially influence phosphatidylinositol 3-kinase signal transduction in endothelial cells: impact on adhesion and apoptosis. Atherosclerosis (2007) 0.83
Dermatomyositis associated with malignant melanoma--a marker of poor prognosis? J Am Acad Dermatol (2006) 0.83
Identification of SPRED2 (sprouty-related protein with EVH1 domain 2) as a negative regulator of the hypothalamic-pituitary-adrenal axis. J Biol Chem (2011) 0.82
Induction of lymphocyte apoptosis in a murine model of acute lung injury--modulation by lipid emulsions. Shock (2010) 0.82
Treatment of severe lichen planus with mycophenolate mofetil. J Am Acad Dermatol (2003) 0.81
A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol (2008) 0.81
Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol (2004) 0.81
Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol (2011) 0.81
Mena/VASP and αII-Spectrin complexes regulate cytoplasmic actin networks in cardiomyocytes and protect from conduction abnormalities and dilated cardiomyopathy. Cell Commun Signal (2013) 0.81
Putative neuronal mechanisms of sensitive skin. Exp Dermatol (2009) 0.81
L-FABP is exclusively expressed in alveolar macrophages within the myeloid lineage: evidence for a PPARalpha-independent expression. Int J Biochem Cell Biol (2004) 0.81
Itch in atopic dermatitis - pathophysiology and treatment. Acta Dermatovenerol Croat (2010) 0.80
Treatment of extra-abdominal aggressive fibromatosis with pegylated interferon. J Am Acad Dermatol (2008) 0.80
Integration of the 1,2,3-triazole "click" motif as a potent signalling element in metal ion responsive fluorescent probes. Chemistry (2013) 0.80
Disseminated giant molluscum contagiosum in a patient with idiopathic CD4+ lymphocytopenia. Successful eradication with systemic interferon. Dermatology (2008) 0.80
Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. J Rheumatol (2015) 0.80
Pathway management in ambulatory wound care: defining local standards for quality improvement and interprofessional care. Int Wound J (2005) 0.79
Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. J Dermatol Sci (2010) 0.79
Modulation of cutaneous inflammation by angiotensin-converting enzyme. J Immunol (2003) 0.79
Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas. Eur J Dermatol (2007) 0.79
NK-1 Antagonists and Itch. Handb Exp Pharmacol (2015) 0.78
Modulation of basophil activity: a novel function of the neuropeptide α-melanocyte-stimulating hormone. J Allergy Clin Immunol (2011) 0.78
Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol (2008) 0.78
The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function. Am J Pathol (2011) 0.78
Monitoring neuropeptide-specific proteases: processing of the proopiomelanocortin peptides adrenocorticotropin and alpha-melanocyte-stimulating hormone in the skin. Exp Dermatol (2006) 0.78
G-DRG Version 2009: new developments. J Dtsch Dermatol Ges (2009) 0.78
Synthesis of cyclometallated platinum complexes with substituted thienylpyridines and detailed characterization of their luminescence properties. Inorg Chem (2009) 0.78